Resistance to rezatapopt: New TP53 mutations identified in cancer patients

COTI-2 has an effect on mutated p53 protein that is similar to that documented for a few other members of the same class of compounds. COTI-2 is a third generation thiosemicarbazone specifically engineered for low toxicity. Other drugs in development target the mdm2 protein leading to increased functional p53 by decreasing the destruction of normal p53 protein. COTI-2 also has a unique effect on the PI3K/AKT pathway via a direct gene level up regulation of a specific protein (PIK3IP) that is known to inhibit PI3K. This means that COTI-2 is potentially effective in cancers with p53 mutations as well as in mutations of the PI3K/AKT pathway. This effect has been confirmed in an animal model of human ovarian cancer.

While we've initiated dialogues on integrating AI, it hasn't transformed our work yet. However, I see it as a significant tool, especially for handling and processing big data. AI can help bridge the expertise gap in understanding both bioinformatics and biological terms, aiding in the efficient mining of information.

Stupp and his team posited that "dancing molecules" might encourage the stubborn tissue to regenerate. Previously invented in Stupp's laboratory, dancing molecules are assemblies that form synthetic nanofibers comprising tens to hundreds of thousands of molecules with potent signals for cells. By tuning their collective motions through their chemical structure, Stupp discovered the moving molecules could rapidly find and properly engage with cellular receptors, which also are in constant motion and extremely crowded on cell membranes. Once inside the body, the nanofibers mimic the extracellular matrix of the surrounding tissue. By matching the matrix's structure, mimicking the motion of biological molecules and incorporating bioactive signals for the receptors, the synthetic materials are able to communicate with cells. "Cellular receptors constantly move around," Stupp said. "By making our molecules move, 'dance' or even leap temporarily out of these structures, known as supramolecular polymers, they are able to connect more effectively with receptors."

This is a win for the field. Until now, we have been focused on immune therapies that might make tumors more vulnerable to the body's immune system, and on finding new chemotherapy combinations that kill cancer cells. This new treatment has given us a new focus, and I think it will spur a lot of scientific discovery over the next few years. There have only been a handful of KRAS researchers and their relevance to therapy was always questioned. That is about to change. The most important next step for the field is to better understand the biology of cancer. We know that many pancreatic tumors will eventually become resistant to daraxonrasib, and we need to understand how this happens. We also need to identify additional genetic pathways and treatments that can target them. That's how we will turn pancreas cancer from a deadly, deadly cancer into something we can manage-and one day, even cure.

For the average adult, the Recommended Dietary Allowance (RDA) for protein or the amount you need to meet your basic nutritional requirements and not get sick, is 0.8 grams of protein per kilogram of body weight, or 0.36 grams per pound. For a person who weighs 75 kg (165 pounds), that comes to 60 grams of protein per day. To determine your target daily protein intake, you can multiply your weight in pounds by 0.36, or use this online calculator. It's important to keep in mind that your daily protein need is not a fixed number. For example, your protein needs will fluctuate depending on your level of physical activity, and whether you are pregnant or breastfeeding.